In vivo visualization of propagating α -synuclein pathologies in mouse and marmoset models by a bimodal imaging probe, C05-05

Authors Maiko Ono1,6*, Manami Takahashi1,6, Aki Shimozawa2, Masayuki Fujinaga1, Wakana Mori1, Yuji Nagai1, Koki Mimura1, Katsushi Kumata1, Tatsuya Kikuchi1, Masafumi Shimojo1, Hiroyuki Takuwa1, Takeharu Minamihisamatsu1, Shoko Uchida1, Sushil K. Mishra3, Yoshiki Yamaguchi4, Hiroshi Shimizu5, Akiyoshi Kakita5, Hironobu Endo1, Yuhei Takado1, Takafumi Minamimoto1, Naruhiko Sahara1, Ming-Rong Zhang1, Masato Hasegawa2, Makoto Higuchi1*

[1]  A. Landau,et al.  [11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  A. Varrone,et al.  Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein , 2020, Brain Research.

[3]  A. Murzin,et al.  Structures of α-synuclein filaments from multiple system atrophy , 2020, Nature.

[4]  A. Murzin,et al.  Novel tau filament fold in corticobasal degeneration , 2020, Nature.

[5]  Samuel T. Slocum,et al.  Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys , 2019, Nature Neuroscience.

[6]  J. Seibyl,et al.  Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study , 2019, The Journal of Nuclear Medicine.

[7]  J. Trojanowski,et al.  α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies , 2019, Neuroscience Letters.

[8]  Ming-Rong Zhang,et al.  Automated Synthesis of (rac)‐, (R)‐, and (S)‐[18F]Epifluorohydrin and Their Application for Developing PET Radiotracers Containing a 3‐[18F]Fluoro‐2‐hydroxypropyl Moiety , 2018, ChemMedChem.

[9]  Alexey G. Murzin,et al.  Structures of filaments from Pick’s disease reveal a novel tau protein fold , 2018, Nature.

[10]  A. Nordberg,et al.  Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding , 2018, Alzheimer's & dementia.

[11]  M. Goedert,et al.  Tau Filaments and the Development of Positron Emission Tomography Tracers , 2018, Front. Neurol..

[12]  Ming-Rong Zhang,et al.  Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models , 2018, The Journal of Nuclear Medicine.

[13]  M. Citron,et al.  The tau positron‐emission tomography tracer AV‐1451 binds with similar affinities to tau fibrils and monoamine oxidases , 2018, Movement disorders : official journal of the Movement Disorder Society.

[14]  R. Barker,et al.  11C‐PE2I and 18F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study , 2018, Movement disorders : official journal of the Movement Disorder Society.

[15]  J. Kordower,et al.  Therapeutic approaches to target alpha-synuclein pathology , 2017, Experimental Neurology.

[16]  M. Higuchi,et al.  Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α‐synuclein pathology , 2017, Movement disorders : official journal of the Movement Disorder Society.

[17]  S. Gauthier,et al.  Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain , 2017, Alzheimer's Research & Therapy.

[18]  M. Hasegawa,et al.  Propagation of pathological α-synuclein in marmoset brain , 2017, Acta neuropathologica communications.

[19]  T. Montine,et al.  Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis , 2017, The Lancet Neurology.

[20]  H. Akiyama,et al.  The Effect of Fragmented Pathogenic α-Synuclein Seeds on Prion-like Propagation* , 2016, The Journal of Biological Chemistry.

[21]  P. McLean,et al.  α-Synuclein Multimers Cluster Synaptic Vesicles and Attenuate Recycling , 2014, Current Biology.

[22]  Lin Xie,et al.  Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.

[23]  J. Joutsa,et al.  Diagnostic accuracy of parkinsonism syndromes by general neurologists. , 2014, Parkinsonism & related disorders.

[24]  Masato Hasegawa,et al.  Prion-like spreading of pathological α-synuclein in brain , 2013, Brain : a journal of neurology.

[25]  E. Masliah,et al.  Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia , 2013, Nature Communications.

[26]  Nam Ki Lee,et al.  Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking , 2013, Proceedings of the National Academy of Sciences.

[27]  J. Trojanowski,et al.  Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.

[28]  Yuji Nagai,et al.  PET Analysis of Dopaminergic Neurodegeneration in Relation to Immobility in the MPTP-Treated Common Marmoset, a Model for Parkinson’s Disease , 2012, PloS one.

[29]  Hiroshi Ito,et al.  Correlation between decreased motor activity and dopaminergic degeneration in the ventrolateral putamen in monkeys receiving repeated MPTP administrations: A positron emission tomography study , 2012, Neuroscience Research.

[30]  Ming-Rong Zhang,et al.  Radiosynthesis and preliminary evaluation of 4-[18F]fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1. , 2011, Bioorganic & medicinal chemistry letters.

[31]  Atsushi Iriki,et al.  Population-averaged standard template brain atlas for the common marmoset (Callithrix jacchus) , 2011, NeuroImage.

[32]  Hiroshi Fukuda,et al.  In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. , 2010, Brain : a journal of neurology.

[33]  W. Woods,et al.  Dynamic transport and localization of alpha-synuclein in primary hippocampal neurons , 2010, Molecular Neurodegeneration.

[34]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[35]  Tetsuya Suhara,et al.  Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.

[36]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[37]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[38]  M. Takei,et al.  Sensitive measurement of positron emitters eluted from HPLC. , 2001, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[39]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[40]  L. Serpell,et al.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Dickson,et al.  Multiple System Atrophy: A Sporadic Synucleinopathy , 1999, Brain pathology.

[42]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[43]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[44]  K. Svoboda,et al.  Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window , 2009, Nature Protocols.

[45]  Hideo Fujiwara,et al.  Accumulation of phosphorylated alpha-synuclein in aging human brain. , 2003, Journal of neuropathology and experimental neurology.

[46]  A. Kakita,et al.  Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. , 1998, Acta neuropathologica.